< Back to companies

Onconaut Therapeutics Incorporated (OTI), A Delaware C-Corporation and Colorado-registered company, is developing precision medicines against molecular targets promoting tumor progression, metastasis, and multi-drug resistance. Lead drugs being developed by OTI are designed to address the unmet needs of cancer patients by halting tumor progression and metastasis at any stage of cancer while synergizing with standard-of-care to overcome drug resistance and eradicate primary tumors and metastatic lesions.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2022
Website
onconaut.com/

Categories

Precision MedicineTherapeuticsDrug DevelopmentCancer

Disease Areas

Technologies

Precision Medicine TechDrug DevelopmentMolecular BiologyTarget Discovery
Only accessible to MedStartr community members. Join now

What do you think of Onconaut?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now